Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	119282
Country	China

Category	Oncology
Manuscript Type	Basic Study
Article Title	IGF2BP1 promotes gastric cancer progression by stabilizing HS6ST2 mRNA in an N6-methyladenosine-dependent manner
Manuscript Source	Unsolicited Manuscript
All Author List	Lu Liu, Yi-Jing Zhou, Yue Xu, Qian-Qian Yin, Jue-Jue Wang, Shan-Jing Xu, Ling-Ling Yan, Zhen-Zhen Wang, Shao-Wei Li, Xin-Li Mao and Yu Zhang
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 82570702 the “Pioneer” and “Leading Goose” Research and Development Program of Zhejiang 2025C02139 Zhejiang Clinovation Pride CXTD202502030 the Medical Science and Technology Project of Zhejiang Province 2025KY1818 the Medical Science and Technology Project of Zhejiang Province 2023KY1312 the Science and Technology Plan Project of Taizhou 22ywb09 the Major Projects of Taizhou Enze Medical Center 2025EZZD02
Corresponding Author	Yu Zhang, Chief Physician, MD, Department of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, Linhai 317000, Zhejiang Province, China. zy@enzemed.com
Key Words	Gastric cancer; HS6ST2; IGF2BP1; N6-methyladenosine modification; Phosphatidylinositol 3-kinase; Protein kinase B; Mammalian target of rapamycin
Core Tip	Insulin-like growth factor 2 mRNA-binding protein (IGF2BP) 1 is an N6-methyladenosine reader that is highly expressed in gastric cancer (GC) and is associated with lymph node metastasis and poor prognosis. This study elucidates the oncogenic mechanism of IGF2BP1 via its downstream target, heparan sulfate 6-O-sulfotransferase 2 (HS6ST2). Both in vitro and in vivo analyses demonstrate that IGF2BP1 stabilizes HS6ST2 mRNA in an N6-methyladenosine-dependent manner, which, in turn, activates the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway, thereby driving GC cell proliferation, invasion, and metastasis. Taken together, these results may identify the IGF2BP1/HS6ST2 axis as a potential prognostic biomarker and therapeutic target in GC.
Citation	Liu L, Zhou YJ, Xu Y, Yin QQ, Wang JJ, Xu SJ, Yan LL, Wang ZZ, Li SW, Mao XL, Zhang Y. IGF2BP1 promotes gastric cancer progression by stabilizing HS6ST2 mRNA in an N6-methyladenosine-dependent manner. World J Gastrointest Oncol 2026; In press

Received	2026-02-06 02:25
Peer-Review Started	2026-02-06 02:26
First Decision by Editorial Office Director	2026-02-14 07:57
Return for Revision	2026-02-14 08:41
Revised	2026-02-28 16:03
Publication Fee Transferred	2026-03-04 11:06
Second Decision by Editor	2026-04-14 02:36
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-04-14 04:07
Articles in Press	2026-04-14 04:07
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com